TCR Transgenic CD8+ T Cells Activated in the Presence of TGFbeta Express FoxP3 and Mediate Linked Suppression of Primary Immune Responses and Cardiac Allograft Rejection
Overview
Affiliations
Although CD4+CD25+FoxP3+ regulatory T cells play a role in allograft tolerance, the role of CD8+ cells with immunosuppressive function is less clear. To address this issue, spleen cells from Rag-1-deficient TCR transgenic (Tg) mice expressing a receptor for ovalbumin (OVA) in the context of MHC class I (OT1) were activated with OVA expressing antigen-presenting cell (APC) in the presence or absence of exogenous transforming growth factor beta (TGFbeta). TGFbeta inhibited the expression of IFN-gamma, granzyme B and the lytic activity of the OT1 T cells while inducing FoxP3 expression in 5-15% of the cells. By contrast, FoxP3 expression was not detected in naive OT-1 T cells or OT-1 T cells activated without exogenous TGFbeta. TGFbeta-activated OT1 cells inhibited the activation of Kd-specific CD8+ CTL responses by normal B6 T cells and the proliferation by Kd-specific CD4+ TCR Tg T cells, but only if the OVA epitope was co-expressed by Kd+ APC. This antigen-specific inhibitory activity, referred to as linked suppression, was neither mediated by residual lytic activity within the activated OT1 T cells nor did it depend upon IL-10 or TGFbeta. Suppression correlated with inhibition of CD86 expression on CD11c+ APC. TGFbeta-activated OT1 T cells also delayed the rejection of heterotopic, vascularized cardiac allografts mediated by anti-Kd-specific CD4+ TCR Tg T cells, but only if the cardiac allograft expressed both OVA and Kd as transgenes. Prolonged survival of allografts was associated with rapid migration of the FoxP3+ OT1 T cells into the donor heart raising the possibility that suppression may be mediated within the allograft. These data show that TGFbeta-activated CD8+ T cells mediate antigen-specific, APC-focused patterns of suppression in vitro and in vivo.
Suppression of Chlamydial Pathogenicity by Nonspecific CD8 T Lymphocytes.
Xie L, He C, Chen J, Tang L, Zhou Z, Zhong G Infect Immun. 2020; 88(10).
PMID: 32747602 PMC: 7504968. DOI: 10.1128/IAI.00315-20.
Cancer Cell-targeted and Activatable Photoimmunotherapy Spares T Cells in a 3D Coculture Model.
Kercher E, Nath S, Rizvi I, Spring B Photochem Photobiol. 2019; 96(2):295-300.
PMID: 31424560 PMC: 7028482. DOI: 10.1111/php.13153.
Moldenhauer L, Diener K, Hayball J, Robertson S Immunol Cell Biol. 2017; 95(8):705-715.
PMID: 28529323 DOI: 10.1038/icb.2017.41.
Kotsiou E, Gribben J, Davies J Mol Ther. 2016; 24(6):1126-1134.
PMID: 27049761 PMC: 4923329. DOI: 10.1038/mt.2016.64.
Ligocki A, Niederkorn J Invest Ophthalmol Vis Sci. 2016; 57(3):813-23.
PMID: 26934137 PMC: 4777277. DOI: 10.1167/iovs.15-18786.